Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov;13(11):6654-6672.
doi: 10.21037/jtd-2021-12.

Bacterial infections in lung transplantation

Affiliations
Review

Bacterial infections in lung transplantation

Margaret McCort et al. J Thorac Dis. 2021 Nov.

Abstract

Lung transplantation has lower survival rates compared to other than other solid organ transplants (SOT) due to higher rates of infection and rejection-related complications, and bacterial infections (BI) are the most frequent infectious complications. Excess morbidity and mortality are not only a direct consequence of these BI, but so are subsequent loss of allograft tolerance, rejection, and chronic lung allograft dysfunction due to bronchiolitis obliterans syndrome (BOS). A wide variety of pathogens can cause infections in lung transplant recipients (LTRs), including a number of nosocomial pathogens and other multidrug-resistant (MDR) pathogens. Although pneumonia and intrathoracic infections predominate, LTRs are at risk of a number of types of infections. Risk factors include altered anatomy and function of airways, impaired immunity, the microbial flora of the donor and recipient, underlying medical conditions, and genetic factors. Further work on immune monitoring has the potential to improve outcomes. The infecting agents can be derived from the donor lung, pre-existing recipient flora, or acquired from the environment over time. Certain infections may preclude lung transplantation, but this varies from center to center, and more recent studies suggest fewer patients should be disqualified. New molecular methods allow microbiome studies of the lung, gut, and other sites that may further our knowledge of how airway colonization can result in infection and allograft loss. Surveillance, early diagnosis, and aggressive antimicrobial therapy of BI is critical in LTRs. Antibiotic resistance is a major barrier to successful management of these infections. The availability of new agents for MDR Gram-negatives may improve outcomes. Other new therapies, such as bacteriophage therapy, show promise for the future. Finally, it is important to prevent infections through peri-transplant prophylaxis, vaccination, and infection control measures.

Keywords: Bacterial infections (BI); lung transplantation.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at: http://dx.doi.org/10.21037/jtd-2021-12). The series “Lung Transplantation: Past, Present, and Future” was commissioned by the editorial office without any funding or sponsorship. The authors have no other conflicts of interest to declare.

References

    1. Burguete S, Diego M, Levin F, et al. Lung transplant infection. Respirology 2013;18:22-38. 10.1111/j.1440-1843.2012.02196.x - DOI - PMC - PubMed
    1. Alexander BD, Tapson VF. Infectious complications of lung transplantation. Transpl Infect Dis 2001;3:128-37. 10.1034/j.1399-3062.2001.003003128.x - DOI - PubMed
    1. Witt CA, Meyers BF, Hachem RR. Pulmonary nfections following lung transplantation. Thorac Surg Clin 2012;22:403-12. 10.1016/j.thorsurg.2012.04.006 - DOI - PMC - PubMed
    1. Gagliotti C, Morsillo F, Moro ML, et al. Infections in liver and lung transplant recipients: a national prospective cohort. Eur J Clin Microbiol Infect Dis 2018;37:399-407. 10.1007/s10096-018-3183-0 - DOI - PubMed
    1. van Delden C, Stampf S, Hirsch H, et al. Burden and timeline of infectious diseazse int he first year after solid orgran transplantation in the Swiss Transplant cohort study. Clin Infect Dis 2020. doi: . 10.1093/cid/ciz1113 - DOI - PMC - PubMed